Drug-related problems in patients with osteoporosis
Abstract
Background/Aim. Drug-related problems are especially frequent among patients suffering from non-communicable diseases, like osteoporosis, leading to suboptimal treatment response. The aim of this study was to identify drug-related problems in patients with osteoporosis. Methods. This cross-sectional prospective study was conducted in January 2014 on outpatients with osteoporosis from three health facilities in Belgrade, Serbia. The patients included in the study were older than 50 years, and they were offered an anonymous questionnaire with open-ended questions. Results. There were 355 study participants, 329 (92.7%) females and 26 (7.3%) males. The patients who experienced at least one osteoporotic fracture (n = 208) were significantly less adherent to the therapy, less engaged in sports and regular physical activities, and more prone to nutrition with inadequate intake of calcium and vitamin D than patients without fractures (n = 147). Conclusion. The effectiveness of osteoporosis treatment is decreased by several drug-related problems encountered by both physicians and patients. However, the majority of the drug-related problems could be greatly influenced by appropriate educational programs.
References
Kempen TG, van de Steeg-van GC, Hoogland P, Liu Y, Bouvy ML. Large scale implementation of clinical medication reviews in Dutch community pharmacies: drug-related problems and interventions. Int J Clin Pharm 2014; 36(3): 630−5.
Cancian M, Battaggia A, Celebrano M, Del Zotti F, Novelletto BF, Michieli R, et al. The care for chronic heart failure by general practitioners. Results from a clinical audit in Italy. Eur J Gen Pract 2013; 19(1): 3−10.
Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFP. Arch Osteoporos 2013; 8(1−2):136.
Lesić A, Jarebinski M, Pekmezović T, Bumbasirević M, Spasovski D, Atkinson HD. Epidemiology of hip fractures in Belgrade, Serbia Montenegro, 1990-2000. Arch Orthop Trauma Surg 2007; 127(3): 179−83.
Salari Sharif P, Abdollahi M, Larijani B. Current, new and future treatments of osteoporosis. Rheumatol Int 2011; 31(3): 289−300.
Machado-Alba J, Alzate-Carvajal V, Mondragón-Cardona A, Jiménez-Canizales CE. Low frequency of prophylaxis prescription for osteoporosis in patients receiving chronic treatment with corticosteroids in Colombia. Rev Peru Med Exp Salud Publica 2013; 30(1): 26−30. (Spanish)
Lai PS, Chua SS, Chan SP. Pharmaceutical care issues encountered by post-menopausal osteoporotic women prescribed bisphosphonates. J Clin Pharm Ther 2012; 37(5): 536−43.
Yu S, Chou C, Lai H, Chen Y, Chiu C, Kuo M, et al. Adherence to anti-osteoporotic regimens in a Southern Taiwanese population treated according to guidelines: a hospital-based study. Int J Rheum Dis 2012; 15(3): 297−305.
Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 2007; 82(12): 1493−501.
Leikola SN, Virolainen J, Tuomainen L, Tuominen RK, Airaksinen MS. Comprehensive medication reviews for elderly patients: Findings and recommendations to physicians. J Am Pharm Assoc 2012; 52(5): 630−3.
Cadarette SM, Carney G, Baek D, Gunraj N, Paterson JM, Dormuth CR. Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage. Osteoporos Int 2012; 23(4): 1475−80.
Segal E, Tamir A, Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 2003; 5(12): 859−62.
La P, Chua SS, Chan SP. Medication adherence and other issues encountered by patients with osteoporosis. Malay J Pharmac Sci 2005; 3(2): 70.
Stuurman-Bieze AG, Hiddink EG, van Boven JF, Vegter S. Proactive pharmaceutical care interventions decrease patients' nonadherence to osteoporosis medication. Osteoporos Int 2014; 25(6): 1807−12.
Imaz I, Zegarra P, González-Enríquez J, Rubio B, Alcazar R, Amate JM. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 2010; 21(11): 1943−51.
Mikyas Y, Agodoa I, Yurgin N. A Systematic Review of Osteoporosis Medication Adherence and Osteoporosis-Related Fracture Costs in Men. Appl Health Econ Health Policy 2014; 12(3): 267−77.
Cesarec G, Martinec S, Basić I, Jakopić D. Effect of exercises on quality of life in women with osteoporosis and osteopenia. Coll Antropol 2014; 38(1): 247−54.
Varacallo MA, Fox EJ. Osteoporosis and its complications. Med Clin North Am 2014; 98(4): 817−31.
Chahal J, Lee R, Luo J. Loading dose of physical activity is related to muscle strength and bone density in middle-aged women. Bone 2014; 67:41-45. doi: 10.1016/j.bone.2014.06.029
Nshimyumukiza L, Durand A, Gagnon M, Douville X, Morin S, Lindsay C, et al. An economic evaluation: Simulation of the cost-effectiveness and cost-utility of universal prevention strategies against osteoporosis-related fractures. J Bone Miner Res 2013; 28(2): 383−94.
Gunn CA, Weber JL, Kruger MC. Diet, weight, cytokines and bone health in postmenopausal women. J Nutr Health Aging 2014; 18(5): 479−86.
Millar H, Davison J. Nutrition education for osteoporosis prevention in men with prostate cancer initiating androgen deprivation therapy. Clin J Oncol Nurs 2012; 16(5): 497−503.